New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer

Maiko Niki, Takashi Yokoi, Takayasu Kurata, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan Background: Several biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NS...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Niki M, Yokoi T, Kurata T, Nomura S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	non-small cell lung cancer platelet-derived microparticle HMGB1 PAI-1 bevacizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a6bca5b1f02e45a4a34f41ea17061e64
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a6bca5b1f02e45a4a34f41ea17061e64
record_format	dspace
spelling	oai:doaj.org-article:a6bca5b1f02e45a4a34f41ea17061e642021-12-02T00:40:49ZNew prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer1179-2728https://doaj.org/article/a6bca5b1f02e45a4a34f41ea17061e642017-08-01T00:00:00Zhttps://www.dovepress.com/new-prognostic-biomarkers-and-therapeutic-effect-of-bevacizumab-for-pa-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Maiko Niki, Takashi Yokoi, Takayasu Kurata, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan Background: Several biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NSCLC). Successful inhibition of angiogenesis with the anti-vascular endothelial growth factor antibody, bevacizumab, has improved the efficacy seen with standard cytotoxic therapy of NSCLC. However, despite such enhanced treatment strategies, the prognosis for patients with advanced NSCLC remains poor. Patients and methods: We assessed potential biomarkers in 161 NSCLC patients and 42 control patients. Enzyme-linked immunosorbent assay methods were used to evaluate three biomarkers: platelet-derived microparticle (PDMP), high-mobility group box-1 (HMGB1), and plasminogen activator inhibitor-1 (PAI-1). We studied the effects of bevacizumab on the expression of these markers. We also analyzed the relationship of the newly designed risk factor (NDRF) to overall survival and disease-free survival. The NDRF classification of patients was determined from the levels of PDMP, HMGB1, and PAI-1. To determine the individual prognostic power of PDMP, HMGB1, and PAI-1, we evaluated associations between their levels and patient outcomes by Kaplan–Meier survival analysis in a derivation cohort. Results: PDMP, HMGB1, and PAI-1 levels were higher in NSCLC patients compared with control patients. Notably, the difference in PDMP levels exhibited the strongest statistical significance (p<0.001). Multivariate analysis showed that HMGB1 and PAI-1 levels were significantly correlated with PDMP levels. Patients who received standard chemotherapy with bevacizumab exhibited significantly reduced levels of all three markers compared with patients who received standard chemotherapy. NDRF3 status (high levels of all three markers) was significantly correlated with a poor prognosis (p<0.05 for overall survival and disease-free survival). Conclusion: Our results demonstrate that abnormal levels of PDMP, HMGB1, and PAI-1 are related to each other in NSCLC. Moreover, our findings suggest that the vascular complications associated with these markers may contribute to a poor prognosis for NSCLC patients. Keywords: non-small-cell lung cancer, platelet-derived microparticle, HMGB1, PAI-1, bevacizumab Niki MYokoi TKurata TNomura SDove Medical Pressarticlenon-small cell lung cancerplatelet-derived microparticleHMGB1PAI-1bevacizumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 91-99 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer platelet-derived microparticle HMGB1 PAI-1 bevacizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer platelet-derived microparticle HMGB1 PAI-1 bevacizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Niki M Yokoi T Kurata T Nomura S New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
description	Maiko Niki, Takashi Yokoi, Takayasu Kurata, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan Background: Several biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NSCLC). Successful inhibition of angiogenesis with the anti-vascular endothelial growth factor antibody, bevacizumab, has improved the efficacy seen with standard cytotoxic therapy of NSCLC. However, despite such enhanced treatment strategies, the prognosis for patients with advanced NSCLC remains poor. Patients and methods: We assessed potential biomarkers in 161 NSCLC patients and 42 control patients. Enzyme-linked immunosorbent assay methods were used to evaluate three biomarkers: platelet-derived microparticle (PDMP), high-mobility group box-1 (HMGB1), and plasminogen activator inhibitor-1 (PAI-1). We studied the effects of bevacizumab on the expression of these markers. We also analyzed the relationship of the newly designed risk factor (NDRF) to overall survival and disease-free survival. The NDRF classification of patients was determined from the levels of PDMP, HMGB1, and PAI-1. To determine the individual prognostic power of PDMP, HMGB1, and PAI-1, we evaluated associations between their levels and patient outcomes by Kaplan–Meier survival analysis in a derivation cohort. Results: PDMP, HMGB1, and PAI-1 levels were higher in NSCLC patients compared with control patients. Notably, the difference in PDMP levels exhibited the strongest statistical significance (p<0.001). Multivariate analysis showed that HMGB1 and PAI-1 levels were significantly correlated with PDMP levels. Patients who received standard chemotherapy with bevacizumab exhibited significantly reduced levels of all three markers compared with patients who received standard chemotherapy. NDRF3 status (high levels of all three markers) was significantly correlated with a poor prognosis (p<0.05 for overall survival and disease-free survival). Conclusion: Our results demonstrate that abnormal levels of PDMP, HMGB1, and PAI-1 are related to each other in NSCLC. Moreover, our findings suggest that the vascular complications associated with these markers may contribute to a poor prognosis for NSCLC patients. Keywords: non-small-cell lung cancer, platelet-derived microparticle, HMGB1, PAI-1, bevacizumab
format	article
author	Niki M Yokoi T Kurata T Nomura S
author_facet	Niki M Yokoi T Kurata T Nomura S
author_sort	Niki M
title	New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
title_short	New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
title_full	New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
title_fullStr	New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
title_full_unstemmed	New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
title_sort	new prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/a6bca5b1f02e45a4a34f41ea17061e64
work_keys_str_mv	AT nikim newprognosticbiomarkersandtherapeuticeffectofbevacizumabforpatientswithnonsmallcelllungcancer AT yokoit newprognosticbiomarkersandtherapeuticeffectofbevacizumabforpatientswithnonsmallcelllungcancer AT kuratat newprognosticbiomarkersandtherapeuticeffectofbevacizumabforpatientswithnonsmallcelllungcancer AT nomuras newprognosticbiomarkersandtherapeuticeffectofbevacizumabforpatientswithnonsmallcelllungcancer
_version_	1718403574002614272

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer

Ejemplares similares